Skip to main content
SpringerLink
Log in

Prognostic significance of preoperative MRI scans in glioblastoma multiforme

  • Clinical Study
  • Published:
Journal of Neuro-Oncology Aims and scope Submit manuscript

Abstract

Tumor necrosis, enhancement, and associated edema in patients with glioblastoma multiforme (GBM) represent biological variables that can be quantitated on preoperative MRI scans. We reviewed 48 highly selected patients, all of whom had supratentorial lesions, had undergone gross total tumor resection, and had received adjuvant treatments (radio- and chemotherapies). None of these patients had had surgery for recurrent tumor resection and none had harbored multifocal tumors. The median age was 50 years. The median Karnofsky performance score was 80. Multivariate analysis using the Cox regression model revealed that the strongest prognostic variable was the amount of tumor necrosis on preoperative scan (P < 0.001), with median survivals of 42, 24, 15, and 12 months for tumor necrosis grades of 0 (7 ‘pts’), I (11 ‘pts’),11 (9 ‘pts’), and III (21 ‘pts’), respectively. The intensity of enhancement of the tumor nodule was another prognostic factor (P = 0.003), with median survivals of 35, 18, and 13.5 months for enhancement grades of 0 (2 ‘pts’), I (22 ‘pts’), and II (24 ‘pts’), respectively. The extent of peritumoral edema had a quadratic effect (P = 0.001), with grades I (19 ‘pts’), II (22 ‘pts’), and III (7 ‘pts’) surviving for 24,12, and 20 months respectively. Location and volume of tumors were not statistically significant predictors of survival (P < 0.05). In conclusion, in this highly selected group, GBM patients with little or no necrosis and with less tumor nodule enhancement on preoperative MRI survive longer than patients with greater amounts of necrosis and greater degrees of tumor enhancement. In addition, a moderate degree of peritumoral edema is associated with worse prognosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Shapiro WR, Green SB, Burger PC, Mahaley MS, Selker RG, Vangilder JC, Robertson JT, Ransohoff J, Mealey J, Strike TA, Pistenmaa DA: Randomized trial of three chemotherapy regimens and two radiotherapy regimens in postoperative treatment of malignant glioma. J Neurosurg 71: 1–9, 1989.

    Google Scholar 

  2. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hant WE, MacCarty CS, Mahaley MS, Mealey J, Owens G, Ransohoff J, Robertson JT, Shapiro WR, Smith KR, Wilson CB, Strike TA: Randomized comparisons of radiotherapy and nitrosoureas for treatment of malignant glioma after surgery. New Engl J Med 303: 1323–1329, 1980.

    Google Scholar 

  3. Soffietti R, Chio A: Prognostic factors in cerebral astrocytic gliomas. In: Broggi C, Gerosa MA (eds) Cerebral Gliomas. Elsevier, Amsterdam, 1989, pp 149–150.

    Google Scholar 

  4. Glibert H, Kagan AR, Cassidy F, Wagner, Fuchs K, Fox D, Glibert D, Rao A, Nussbaum H, Forsythe A, Eder D, Latine, Youleless L, Chan P, Hintz BL: Glioblastoma multiforme is not a uniform disease. Cancer Clin Trials 4: 87–89, 1981.

    Google Scholar 

  5. Ammirati M, Vick N, Liao Y, Ciric I, Mikhael M: Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 201–206, 1987.

    Google Scholar 

  6. Gehan EA, Walker MD: Prognostic factors for patients with brain tumors. Natl Cancer Inst Monograph 46: 189–195, 1977.

    Google Scholar 

  7. Scott GM, Gibberd FB: Epilepsy and other factors in the prognosis of gliomas. Acta Neurol Scandinav 61: 227–239, 1980.

    Google Scholar 

  8. Ammirati M, Galicich JH, Arbit E: Reoperation in the treatment of recurrent intracranial malignant gliomas. Neurosurgery 21: 607–613, 1987.

    Google Scholar 

  9. Harch GR, Levin VA, Gutin PH, Seager M, Silver P, Wilson CB: Reoperation for recurrent glioblastoma and anaplastic astrocytoma. Neurosurgery 21: 615–620, 1987.

    Google Scholar 

  10. Burger PC, Vogel FS, Green SB, Strike TA: Glioblastoma multiforme and anaplastic astrocytoma: Pathologic criteria and prognostic implications. Cancer 56: 1106–1111, 1985.

    Google Scholar 

  11. Salcman M: Survival in glioblastoma: Historical perspective. Neurosurgery 7: 435–438, 1980.

    Google Scholar 

  12. Mahaley MS, Mettlin C, Natazajan N, Laws ER, Peace B: National survey of patterns of care for brain tumor patients. J Neurosurg 71: 826–836, 1989.

    Google Scholar 

  13. Nelson JS, Tsukada Y, Schoenfeld D, Fulling K, Lamarche J, Peress N: Necrosis as a prognostic criterion in malignant supratentorial astrocytric gliomas. Cancer 52: 550–554, 1983.

    Google Scholar 

  14. Forsting M, Albert FK, Sartor K: CT and MRI after brain tumor resection: How to obtain useful baseline scan. Tumor response monitoring and treatment planning. ART 91: 103, 1984.

    Google Scholar 

  15. Karnofsky DA, Barchend LJH, Armstead GC, Southam CM, Bernstein JL, Craer LF, Rhoads CP: Triethyline melanine in the treatment of neoplastic disease. Arch Intern Med 87: 477–516, 1951.

    Google Scholar 

  16. Bradley NJ, Bloom HJC, Davies AJS, Swift SM: Growth of human gliomas in immuno-deficient mice: A possible model for pre-clinical therapy. Br J Cancer 38: 263–272, 1978.

    Google Scholar 

  17. Bullard DE, Schold SC Jr, Bigner SH, Bigner DD: Growth and chemotherapeutic response in athymic mice of tumors arising from human glioma-derived cell lines. J Neuropathol Exp Neurol 40: 410–427, 1981.

    Google Scholar 

  18. Cox DR: Regression models and life tables. JR Stat Soc B34: 187–220, 1972.

    Google Scholar 

  19. Kaplan EL, Meier P: Non-parametric estimation from incomplete observation. J Am Star Assoc 53: 457–481, 1958.

    Google Scholar 

  20. Pigott TJ: Clinical and cellular prognostic variables in glioblastoma multiforme. Diss Abstr Int B (abstract) 52 (5): 2495, 1991.

    Google Scholar 

  21. Michael MT, Beale SA: Magnetic resonance imaging of supratentorial neoplasms. In: Wilkins RH, Rengachary SS (eds) Neurosurgery Update I. McGraw-Hill Co., San Francisco, 1990, pp 12–28.

    Google Scholar 

  22. Alvord EC Jr: Is necrosis helpful in the grading of gliomas? Editorial opinion. J Neuropathol Exp Neurol 51 (2): 127–132, 1992.

    Google Scholar 

  23. Segall HD, Destian S, Nelson MD Jr, Zee CS, Ahmadi J: CT and MR imaging in malignant gliomas. In: Apuzzo MLJ (ed) Malignant Cerebral Gliomas. AANS, Illinois, 1990, pp 63–77.

    Google Scholar 

  24. Front D, Israel O, Kohn S, Nit I: The blood tissue barrier of human brain tumors: Correlation of scintigraphic and ultrastructural findings-concise communication. J Nucl Med 25: 461–465, 1984.

    Google Scholar 

  25. Sage MR: Blood-brain barrier: Phenomenon of increasing importance to the imaging clinician. Am J Neuroradiol 138: 887–898, 1982.

    Google Scholar 

  26. Earnest FI, Kelly PJ, Scheithauer BW, Kall BA, Cascino TL, Ehman RL, Forbes GS, Axley PL: Cerebral astrocytomas: Histopathological correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 166: 823–827, 1988.

    Google Scholar 

  27. Hirano A, Matsui T: Vascular structures in brain tumors. Hum Pathol 6: 611–621, 1975.

    Google Scholar 

  28. Long DM: Capillary ultrastructure and the blood-brain barrier in human malignant brain tumors. J Neurosurg 32: 127–144, 1970.

    Google Scholar 

  29. Caillé JM, Guibert-Tranier F, Calabet A, Billerey J, Piton J: Abnormal enhancements after contrast injection. In: Caillé JM, Salamon G (eds) Computerized Tomography. Berlin Springer, 1980, pp 166–171.

    Google Scholar 

  30. Bydder GM: Gd-DTPA finds its place in brain and cord imaging. Diagn Imaging 57: 212–217, 1988.

    Google Scholar 

  31. Chamberlin MC, Murovic JA, Levin VA: Absence of contrast enhancement on CT brain scans of patients with supratentorial malignant gliomas. Neurology 38: 1371–1374, 1988.

    Google Scholar 

  32. Bydder GM, Steiner RE, Thomas DJ, Marshall J, Gildendale DJ, Young IR: Nuclear magnetic resonance imaging of the posterior fossa: 50 cases. Clin Radiol 34: 173–188, 1983.

    Google Scholar 

  33. Randell CP, Collins AG, Young IR: Nuclear magnetic resonance imaging of posterior fossa tumors. Am J Roentgenol 141: 489–496, 1986.

    Google Scholar 

  34. Levin VA, Hoffman WF, Heilbron DC, Norman D: Prognostic significance of the pretreatment CT scan on time to progression for patients with malignant gliomas. J Neurosurg 52: 642–647, 1980.

    Google Scholar 

  35. Sawaya R: The fibrinolytic enzymes in the biology of brain tumors. In: Sawaya R (ed) Fibrinolysis and the Central Nervous System. Hanley and Belfus, Inc., Philadelphia, 1990, pp 106–126.

    Google Scholar 

  36. Sawaya R, Rämö J, Shi ML, Mandybur G: Biological significance of tissue plasminogen activator content in brain tumors. J Neurosurg 74: 480–486, 1991.

    Google Scholar 

  37. Felix R, Schörner W, Laniado M, Niendrof HP, Claussen C, Fiegler W, Speck U: Brain tumors: MR imaging with gadolinium-DTPA. Radiology 156: 681–688, 1985.

    Google Scholar 

  38. Wood JR, Green SB, Shapiro WR: The prognostic importance of tumor size in malignant gliomas: A computed tomographic scan study by the Brain Tumor Cooperative Group. J Clin Oncol 6(2): 338–343, 1988.

    Google Scholar 

  39. Reeves GI, Marks JE: Prognostic significance of lesion size for glioblastoma multiforme. Radiology 132: 469–471, 1979.

    Google Scholar 

  40. Onoyama Y, Abe M, Yabumoto E, Sakamoto T, Nishidai T, Suyama S: Radiation therapy in the treatment of glioblastomas. Am J Roentgenol 126(3): 481–492, 1976.

    Google Scholar 

  41. Byar DP, Green SB, Strike TA: Prognostic factors for malignant glioma. In: Walker MD (ed) Oncology of the Nervous System. Martinus Nijhoff, Boston, 1983, pp 379–395.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurosurgery, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Maarouf A. Hammoud, Raymond Sawaya & Weiming Shi

  2. Department of Biomathematics, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Peter F. Thall

  3. Section of Neuroradiology, The University of Texas M.D. Anderson Cancer Center, Houston, Texas, USA

    Norman E. Leeds

Authors
  1. Maarouf A. Hammoud
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Raymond Sawaya
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Weiming Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Peter F. Thall
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norman E. Leeds
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Hammoud, M.A., Sawaya, R., Shi, W. et al. Prognostic significance of preoperative MRI scans in glioblastoma multiforme. J Neuro-Oncol 27, 65–73 (1996). https://doi.org/10.1007/BF00146086

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00146086

Key words

Search

Navigation